Elsevier

The Lancet

Volume 379, Issue 9830, 26 May–1 June 2012, Page 1948
The Lancet

Correspondence
Pregnancy should not rule out 18FDG PET/CT for women with cancer

https://doi.org/10.1016/S0140-6736(12)60851-4Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (10)

  • Radiation Absorbed Dose to the Embryo and Fetus from Radiopharmaceuticals

    2022, Seminars in Nuclear Medicine
    Citation Excerpt :

    Opinions differ on what constitutes an acceptable cost-benefit ratio. Papers published by The Lancet explicitly discouraged the use of 18F-FDG in pregnant women with gynecological and hematological cancers,62,63 but such a radical stance is uncommon in the field, where most authors and scientific organizations recognize that clinically justified PET scans should be performed.64-66 More often, the necessity of performing the examination is not in question; rather, dose-optimization recommendations specific to pregnant women are made.

  • Performing nuclear medicine examinations in pregnant women

    2017, Physica Medica
    Citation Excerpt :

    In a series of papers about the management of pregnant women with gynecological and hematological cancers published by the Lancet, the use of 18F-FDG in pregnant women was explicitly discouraged [9,10]. It is our contention that medically justified examinations should not be withheld in pregnant women for fear of radiation exposure [11]. Once the decision to perform the examination in the pregnant patient is taken, preserving the diagnostic power of the examination is of paramount importance.

  • Contrast Agents during Pregnancy: Pros and Cons When Really Needed

    2022, International Journal of Environmental Research and Public Health
View all citing articles on Scopus
View full text